| Literature DB >> 25083364 |
Michael S Nickoli1, Wellington K Hsu1.
Abstract
Study Design Systematic review. Objective Ceramic-based bone grafts have been widely utilized to reduce the need for iliac crest bone grafting given the complications associated with the harvest of iliac crest autograft. As a family, ceramics vary widely based on differences in composition, manufacturing, porosity, and structure, which may ultimately affect their efficacy. This article reviews the current data of ceramics used in different environments in the lumbar spine to achieve arthrodesis. Methods Medline, EMBASE, and Cochrane Central Register of Controlled Trials were searched for publications from 1980 to 2013 involving ceramic-based bone grafts in the lumbar spine. Variables such as age of patients, volume of ceramic, procedure, time to evaluation, method of evaluation, specific composition of ceramic, adjuncts used with ceramic products, type of fusion, and fusion rate were compared using a multivariate logistic regression model. Results Thirty studies with 1,332 patients met the final inclusion criteria. The overall fusion rate for all ceramic products as a bone graft extender in the lumbar spine was 86.4%. Age, gender, method of evaluation (plain radiographs, computed tomography, or combination), or specific ceramic product did not significantly affect fusion rate. Ceramics used in combination with local autograft resulted in significantly higher fusion rates compared with all other adjuncts, and bone marrow aspirate and platelet concentrates resulted in significantly lower fusion rates. Conclusions Ceramic-based bone grafts represent a promising bone graft extender in lumbar spine fusion when an osteoinductive stimulus, such as local bone graft is available.Entities:
Keywords: ceramics; lumbar spine; spinal fusion; systematic review
Year: 2014 PMID: 25083364 PMCID: PMC4111951 DOI: 10.1055/s-0034-1378141
Source DB: PubMed Journal: Global Spine J ISSN: 2192-5682
Fig. 1Query results and exclusion.
Fusion rate by X-ray versus CT
| Number of studies | Total patients | Number fused | Fusion rate (%) | Range (%) | |
|---|---|---|---|---|---|
| X-ray only | 12 | 581 | 502 | 86.4 | 4.5–100 |
| X-ray and CT | 14 | 615 | 531 | 86.3 | 45.5–95 |
| CT only | 4 | 136 | 118 | 86.8 | 79.5–95.5 |
Abbreviation: CT, computed tomography.
Level of evidence
| Level of evidence | Number of studies |
|---|---|
| Level I | 3 |
| Level II | 9 |
| Level III | 4 |
| Level IV | 14 |
Fusion rate by adjunct
| Number of studies | Total patients | Number fused | Fusion rate (%) | Range (%) | |
|---|---|---|---|---|---|
| Ceramic + local autograft | 10 | 453 | 407 | 89.8 | 52.6–100 |
| Ceramic + BMA | 9 | 215 | 156 | 72.6 | 4.5–95.5 |
| Ceramic + local autograft + BMA | 5 | 242 | 221 | 91.3 | 85–95 |
| Ceramic + iliac crest autograft | 4 | 87 | 77 | 88.5 | 78.9–100 |
| Ceramic alone | 2 | 69 | 56 | 81.2 | 77.6–90 |
| Ceramic + DBM | 1 | 50 | 48 | 96.0 | NA |
| Ceramic + iliac crest autograft +DBM | 1 | 28 | 25 | 89.3 | NA |
| Ceramic + local autograft + iliac crest autograft | 1 | 26 | 25 | 96.2 | NA |
| Ceramic + local autograft + platelet concentrate | 2 | 101 | 79 | 78.2 | 77.3–96 |
Abbreviations: BMA, bone marrow aspirate; DBM, demineralized bone matrix; NA, not applicable.
Fusion rate by procedure
| Number of studies | Total patients | Number fused | Fusion rate (%) | Range (%) | |
|---|---|---|---|---|---|
| Posterolateral fusion | 24 | 994 | 851 | 85.6 | 4.5–100 |
| Circumferential fusion (PLIF, ALIF, TLIF with posterior instrumentation) | 12 | 338 | 300 | 88.8 | 77.3–100 |
Abbreviations: ALIF, anterior lumbar interbody fusion; PLIF, posterior lumbar interbody fusion; TLIF, transforaminal lumbar interbody fusion.
Fusion rate by product
| Number of studies | Total patients | Number fused | Fusion rate (%) | Range (%) | |
|---|---|---|---|---|---|
| Beta tricalcium phosphate (Vitoss; Stryker, Kalamazoo, MI) | 7 | 345 | 319 | 92.5 | 85–100 |
| Calcium sulfate (Osteoset; Wright Medical Technology, Memphis, TN) | 6 | 353 | 306 | 86.7 | 45.5–92.4 |
| Tricalcium phosphate/hydroxyapatite (BCP-BiCalPhos; Medtronic Sofamor Danek, Memphis, TN) | 4 | 152 | 127 | 83.6 | 74.6–92.5 |
| Coralline hydroxyapatite (Pro-Osteon 200, Pro-Osteon 500; Biomet, Warsaw, IN) | 7 | 168 | 146 | 86.9 | 52.6–100 |
| Type I collagen/hydroxyapatite (Healos; Depuy Synthes, Warsaw, IN) | 5 | 97 | 83 | 85.6 | 77.3–95.5 |
| Apatite-wollastonite-containing glass ceramic | 2 | 36 | 36 | 100.0 | NA |
| Dense hydroxyapatite block | 1 | 26 | 25 | 96.2 | NA |
| Synthetic hydroxyapatite (Bongros; Daewoong Bio, Inc., Seoul, Korea) | 1 | 45 | 39 | 86.7 | NA |
| Silicate-substituted calcium phosphate | 1 | 49 | 38 | 77.6 | NA |
| Silicated hydroxyapatite (Actifuse; Baxter, Deerfield, IL) | 1 | 39 | 31 | 79.5 | NA |
| Hydroxyapatite-bioactive glass (Chitra-HABg; Sree Chitra Tirunal, Trivandrum, India) | 1 | 22 | 1 | 4.5 | NA |
Abbreviation: NA, not applicable.